Surrozen, Inc.
SRZNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSurrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Valued at $255.0M, SRZN is a micro-cap name in its sector. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Market Cap
$255.0M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
-5.51
EPS (TTM)
$-38.67
EPS (Fwd)
$-3.98
ROE
—
ROA
-22.8%
Cash
$106.9M
Total Debt
$6.8M
Free CF
-$26.1M
52W Change
159.0%
Annual Financials
Cash vs Debt
With $106.9M in cash and $6.8M in debt, SRZN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$26.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
The relatively low beta of 0.51 suggests SRZN is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Surrozen, Inc. and its sector.